Loading...
Loading...
Alnylam
Pharmaceuticals, Inc.
ALNY, a
leading RNAi therapeutics company, today announced initial positive
results from its ongoing Phase 1/2 clinical trial with ALN-CC5, an
investigational RNAi therapeutic targeting complement component C5 for
the treatment of complement-mediated diseases. These new
clinical data are being presented at the 20th Congress of
the European Hematology Association (EHA) held June 11 – 14 in Vienna,
Austria. Initial study results from 12 healthy volunteer subjects showed
that single subcutaneous dose administration of ALN-CC5 resulted in
potent, dose-dependent, durable, and statistically significant knockdown
of serum C5 of up to 96%. In addition, single dose administration of
ALN-CC5 achieved inhibition of serum complement activity of up to 92%,
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in